APA (7th ed.) Citation

ML, J., Z, Z., K, L., A, H., BC, C., V, G., . . . J, B. (2021). Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16(9), 1570. https://doi.org/10.1016/j.jtho.2021.03.012

Chicago Style (17th ed.) Citation

ML, Johnson, et al. "Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 16, no. 9 (2021): 1570. https://doi.org/10.1016/j.jtho.2021.03.012.

MLA (9th ed.) Citation

ML, Johnson, et al. "Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 16, no. 9, 2021, p. 1570, https://doi.org/10.1016/j.jtho.2021.03.012.